Reviva Pharmaceuticals Holdings Stock Probability of Future Stock Price Finishing Over 60.01

RVPHW Stock  USD 0.21  0.03  16.67%   
Reviva Pharmaceuticals' future price is the expected price of Reviva Pharmaceuticals instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Reviva Pharmaceuticals Holdings performance during a given time horizon utilizing its historical volatility. Check out Reviva Pharmaceuticals Backtesting, Reviva Pharmaceuticals Valuation, Reviva Pharmaceuticals Correlation, Reviva Pharmaceuticals Hype Analysis, Reviva Pharmaceuticals Volatility, Reviva Pharmaceuticals History as well as Reviva Pharmaceuticals Performance.
  
At this time, Reviva Pharmaceuticals' Price Book Value Ratio is fairly stable compared to the past year. Price Earnings To Growth Ratio is expected to grow at the current pace this year, whereas Price To Operating Cash Flows Ratio is likely to drop (4.54) in 2024. Please specify Reviva Pharmaceuticals' target price for which you would like Reviva Pharmaceuticals odds to be computed.

Reviva Pharmaceuticals Target Price Odds to finish over 60.01

The tendency of Reviva Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move over $ 60.01  or more in 90 days
 0.21 90 days 60.01 
close to zero percent
Based on a normal probability distribution, the odds of Reviva Pharmaceuticals to move over $ 60.01  or more in 90 days from now is close to zero percent (This Reviva Pharmaceuticals Holdings probability density function shows the probability of Reviva Stock to fall within a particular range of prices over 90 days) . Probability of Reviva Pharmaceuticals price to stay between its current price of $ 0.21  and $ 60.01  at the end of the 90-day period is about 31.55 .
Assuming the 90 days horizon Reviva Pharmaceuticals has a beta of 0.13 indicating as returns on the market go up, Reviva Pharmaceuticals average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Reviva Pharmaceuticals Holdings will be expected to be much smaller as well. In addition to that Reviva Pharmaceuticals Holdings has an alpha of 2.6723, implying that it can generate a 2.67 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Reviva Pharmaceuticals Price Density   
       Price  

Predictive Modules for Reviva Pharmaceuticals

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Reviva Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
0.010.1620.05
Details
Intrinsic
Valuation
LowRealHigh
0.010.1720.06
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Reviva Pharmaceuticals. Your research has to be compared to or analyzed against Reviva Pharmaceuticals' peers to derive any actionable benefits. When done correctly, Reviva Pharmaceuticals' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Reviva Pharmaceuticals.

Reviva Pharmaceuticals Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Reviva Pharmaceuticals is not an exception. The market had few large corrections towards the Reviva Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Reviva Pharmaceuticals Holdings, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Reviva Pharmaceuticals within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
2.67
β
Beta against Dow Jones0.13
σ
Overall volatility
0.08
Ir
Information ratio 0.12

Reviva Pharmaceuticals Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Reviva Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Reviva Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Reviva Pharmaceuticals is way too risky over 90 days horizon
Reviva Pharmaceuticals has some characteristics of a very speculative penny stock
Reviva Pharmaceuticals appears to be risky and price may revert if volatility continues
Reviva Pharmaceuticals Holdings has accumulated 17.98 M in total debt. Reviva Pharmaceuticals has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Note, when we think about Reviva Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Net Loss for the year was (39.26 M) with profit before overhead, payroll, taxes, and interest of 0.
Reviva Pharmaceuticals Holdings has accumulated about 353.26 K in cash with (28.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02.
Reviva Pharmaceuticals has a poor financial position based on the latest SEC disclosures
Latest headline from news.google.com: CNS Drug-Maker Reviva Announces 18M Public Offering of Common Stock and Warrants to Fund RD - geneonline

Reviva Pharmaceuticals Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Reviva Stock often depends not only on the future outlook of the current and potential Reviva Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Reviva Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding23.8 M
Cash And Short Term Investments23.4 M

Reviva Pharmaceuticals Technical Analysis

Reviva Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. Reviva Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Reviva Pharmaceuticals Holdings. In general, you should focus on analyzing Reviva Stock price patterns and their correlations with different microeconomic environments and drivers.

Reviva Pharmaceuticals Predictive Forecast Models

Reviva Pharmaceuticals' time-series forecasting models is one of many Reviva Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Reviva Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Reviva Pharmaceuticals

Checking the ongoing alerts about Reviva Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Reviva Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Reviva Pharmaceuticals is way too risky over 90 days horizon
Reviva Pharmaceuticals has some characteristics of a very speculative penny stock
Reviva Pharmaceuticals appears to be risky and price may revert if volatility continues
Reviva Pharmaceuticals Holdings has accumulated 17.98 M in total debt. Reviva Pharmaceuticals has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Note, when we think about Reviva Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Net Loss for the year was (39.26 M) with profit before overhead, payroll, taxes, and interest of 0.
Reviva Pharmaceuticals Holdings has accumulated about 353.26 K in cash with (28.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02.
Reviva Pharmaceuticals has a poor financial position based on the latest SEC disclosures
Latest headline from news.google.com: CNS Drug-Maker Reviva Announces 18M Public Offering of Common Stock and Warrants to Fund RD - geneonline

Additional Tools for Reviva Stock Analysis

When running Reviva Pharmaceuticals' price analysis, check to measure Reviva Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Reviva Pharmaceuticals is operating at the current time. Most of Reviva Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Reviva Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Reviva Pharmaceuticals' price. Additionally, you may evaluate how the addition of Reviva Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.